Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | GRK2 | P25098 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283810 | 0.94 | ABCC4 (0.64) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL18892653 | 0.84 | ALDH1A1 (0.43) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL69614 | 0.83 | CA2 (0.79) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL14886224 | 0.82 | RAB9A (0.60) | LMNAHTTSRD5A2ALDH1A1HPGD | |
| SCHEMBL276932 | 0.81 | CA2 (0.62) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL10656425 | 0.80 | POLB (0.48) | CA2LMNAGAAALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL25180348 | 0.80 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL6765874 | 0.80 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL28158137 | 0.79 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL1290930 | 0.78 | KMT2A (0.58) | CA2LMNATSHRSRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266318-B | Polysiloxane compound, method for preparing the same, and copolycarbonate resin comprising the same | LG化学株式会社 | 2020-07-03 | — | — | CN | claimed |
| CN-119570025-A | Polyethyleneimine derivative and application thereof as gene medicine carrier | 中国药科大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-101952263-A | Romp-polymerizable electron transport materials based on a bis-oxadiazole moiety | GEORGIA TECH RES INST | 2011-01-19 | — | — | CN | disclosed |
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1945641-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| WO-2007044933-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-0046144-B1 | THERAPEUTICALLY ACTIVE DERIVATIVES OF PHENYLETHANOL AMINES | Aktiebolaget Draco (SE) | 1984-04-11 | — | — | EP | disclosed |
| US-4442300-A | BRONCHOSPASMOLYTIC | AKTIEBOLAGET DRACO (SE) | 1984-04-10 | — | — | US | disclosed |
| EP-0046144-A1 | Therapeutically active derivatives of phenylethanol amines | Aktiebolaget Draco (SE) | 1982-02-17 | — | — | EP | disclosed |
| US-4044147-A | N-(acyl)-p-amino-N'-(monosubstituted)-benzamide anti-ulcer agents | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093414-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, PYGL | CA2 4578/4885CAMK2A 4067/4885AKR1B1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.